Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03091439 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis
A Phase 2 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03091439: Clinical Trial Phase 2 study, sponsored by Allergan.
NCT03091439 is a Phase 2 study that was terminated before completion, run by Allergan. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03091439, a Phase 2 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This clinical study will be a multi-center, randomized, open-label, active-controlled, parallel-group study comparing dalbavancin to standard of care (SOC) therapy in osteomyelitis.
Primary Outcome
Clinical response can be either cure, failure, or indeterminate. Cure was defined as recovery without need for additional antibiotic therapy. Failure was defined as the requirement of additional antibiotic therapy, new purulence, amputation due to progression of infection, requiring \> 6 weeks of treatment in the SOC arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency. The number of participants in each response category is re
Interventions
- DRUG Standard of Care
- DRUG Dalbavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2017-08-31 |
| Phase | Phase 2 |
Why NCT03091439 stopped before completion
NCT03091439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT03091439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03091439 about?
NCT03091439 is a clinical study titled "Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis". This clinical study will be a multi-center, randomized, open-label, active-controlled, parallel-group study comparing dalbavancin to standard of care (SOC) therapy in osteomyelitis.
What is the current status of trial NCT03091439?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2017-05-15. Estimated completion is 2017-08-31.
What interventions are being tested in trial NCT03091439?
The interventions under investigation include: Standard of Care (DRUG), Dalbavancin (DRUG).
Who is sponsoring clinical trial NCT03091439?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03091439's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI